Taysha Gene Therapies, Inc. Operating Leases, Future Minimum Payments, Remainder of Fiscal Year
Taysha Gene Therapies, Inc. (TSHA) had Operating Leases, Future Minimum Payments, Remainder of Fiscal Year of $4.85 million as of 2021-12-31, per its 10-K filed 2023-03-28.
Discontinued › Notes › Leases
us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear · last filed 2023-03-28
- 2021-12-31: Operating Leases, Future Minimum Payments, Remainder of Fiscal Year $4.85M.
| Period end | Operating Leases, Future Minimum Payments, Remainder of Fiscal Year |
|---|---|
| 2021-12-31 | $4.85M 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |